Pharmaceuticals in Hungary
Published: November 2012 · Publisher: MarketLine
Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016).
- Description
- Table of Contents
- Ask a Question
Introduction
Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Hungary pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Hungarian pharmaceuticals market had total revenues of $2.4 billion in 2011, representing a compound annual growth rate (CAGR) of 3.3% between 2007 and 2011.
*0
*The performance of the market is forecast to decline, with an anticipated compound annual rate of change (CARC) of -1.3% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $2.2 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Hungary
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Hungary
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Hungary pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Hungary economy
Key Questions Answered
What was the size of the Hungary pharmaceuticals market by value in 2011?
What will be the size of the Hungary pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Hungary pharmaceuticals market?
How has the market performed over the last five years?
Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Hungary pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Hungarian pharmaceuticals market had total revenues of $2.4 billion in 2011, representing a compound annual growth rate (CAGR) of 3.3% between 2007 and 2011.
*0
*The performance of the market is forecast to decline, with an anticipated compound annual rate of change (CARC) of -1.3% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $2.2 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Hungary
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Hungary
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Hungary pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Hungary economy
Key Questions Answered
What was the size of the Hungary pharmaceuticals market by value in 2011?
What will be the size of the Hungary pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Hungary pharmaceuticals market?
How has the market performed over the last five years?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Gedeon Richter Plc 20
EGIS Pharmaceuticals Plc 23
Novartis AG 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: Hungary pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Hungary pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Hungary pharmaceuticals market share: % share, by value, 2011 10
Table 4: Hungary pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Gedeon Richter Plc: key facts 20
Table 6: Gedeon Richter Plc: key financials ($) 21
Table 7: Gedeon Richter Plc: key financials (HUF) 21
Table 8: Gedeon Richter Plc: key financial ratios 21
Table 9: EGIS Pharmaceuticals Plc: key facts 23
Table 10: EGIS Pharmaceuticals Plc: key financials ($) 24
Table 11: EGIS Pharmaceuticals Plc: key financials (HUF) 24
Table 12: EGIS Pharmaceuticals Plc: key financial ratios 24
Table 13: Novartis AG: key facts 26
Table 14: Novartis AG: key financials ($) 27
Table 15: Novartis AG: key financial ratios 27
Table 16: Hungary size of population (million), 2007–11 29
Table 17: Hungary gdp (constant 2000 prices, $ billion), 2007–11 29
Table 18: Hungary gdp (current prices, $ billion), 2007–11 29
Table 19: Hungary inflation, 2007–11 30
Table 20: Hungary consumer price index (absolute), 2007–11 30
Table 21: Hungary exchange rate, 2007–11 30
LIST OF FIGURES
Figure 1: Hungary pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Hungary pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Hungary pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Hungary pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Hungary, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Hungary, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Hungary, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Hungary, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Hungary, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Hungary, 2011 19
Figure 11: Gedeon Richter Plc: revenues & profitability 22
Figure 12: Gedeon Richter Plc: assets & liabilities 22
Figure 13: EGIS Pharmaceuticals Plc: revenues & profitability 25
Figure 14: EGIS Pharmaceuticals Plc: assets & liabilities 25
Figure 15: Novartis AG: revenues & profitability 28
Figure 16: Novartis AG: assets & liabilities 28
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
Gedeon Richter Plc 20
EGIS Pharmaceuticals Plc 23
Novartis AG 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: Hungary pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Hungary pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Hungary pharmaceuticals market share: % share, by value, 2011 10
Table 4: Hungary pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: Gedeon Richter Plc: key facts 20
Table 6: Gedeon Richter Plc: key financials ($) 21
Table 7: Gedeon Richter Plc: key financials (HUF) 21
Table 8: Gedeon Richter Plc: key financial ratios 21
Table 9: EGIS Pharmaceuticals Plc: key facts 23
Table 10: EGIS Pharmaceuticals Plc: key financials ($) 24
Table 11: EGIS Pharmaceuticals Plc: key financials (HUF) 24
Table 12: EGIS Pharmaceuticals Plc: key financial ratios 24
Table 13: Novartis AG: key facts 26
Table 14: Novartis AG: key financials ($) 27
Table 15: Novartis AG: key financial ratios 27
Table 16: Hungary size of population (million), 2007–11 29
Table 17: Hungary gdp (constant 2000 prices, $ billion), 2007–11 29
Table 18: Hungary gdp (current prices, $ billion), 2007–11 29
Table 19: Hungary inflation, 2007–11 30
Table 20: Hungary consumer price index (absolute), 2007–11 30
Table 21: Hungary exchange rate, 2007–11 30
LIST OF FIGURES
Figure 1: Hungary pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Hungary pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Hungary pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Hungary pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Hungary, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Hungary, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Hungary, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Hungary, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Hungary, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Hungary, 2011 19
Figure 11: Gedeon Richter Plc: revenues & profitability 22
Figure 12: Gedeon Richter Plc: assets & liabilities 22
Figure 13: EGIS Pharmaceuticals Plc: revenues & profitability 25
Figure 14: EGIS Pharmaceuticals Plc: assets & liabilities 25
Figure 15: Novartis AG: revenues & profitability 28
Figure 16: Novartis AG: assets & liabilities 28
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.